Aerosol drug formulations
AssigneeGlaxo Inc.
InventorKeith A. Johnson
Life of this patent
Estimating the term…
Abstract
This invention relates to aerosol inhalation drug formulations comprising one or more drugs and one or more soluble surfactants in propellant 134a.
Claims21
An aerosol inhalation drug formulation consisting essentially of a physiologically effective amount of a micronized inhalation drug and a 1,1,1,2-tetrafluoroethane-soluble, perfluoronated surfactant in suspension in 1,1,1,2-tetrafluoroethane.
A method of improving the stability of a micronized, aerosol inhalation drug suspension in 1,1,1,2-tetrafluoroethane consisting essentially of the addition of a 1,1,1,2-tetrafluoroethane-soluble, perfluoronated surfactant to said suspension.
An aerosol inhalation drug formulation consisting essentially of a physiologically effective amount of micronized drug selected from the group albuterol, salmeterol and amiloride or a pharmaceutically acceptable salt thereof, a 1,1,1,2-tetrafluoroethane-soluble, perfluoronated surfactant in suspension in 1,1,1,2-tetrafluoroethane wherein the ratio of said surfactant to said drug is from about 1:100 to about 1:05 by weight and the ratio of drug to 1,1,1,2-tetrafluoroethane is from about 1:100 to about 1:4000 by weight.
Dependencies are inferred from the claim text.